rofecoxib has been researched along with Thrombosis in 31 studies
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using an intention-to-treat analysis of adjudicated CVT deaths, we analyzed detailed patient-level data collected during 3 randomized placebo-controlled trials of rofecoxib versus placebo that had been designed to define the drug's possible role in the prevention or treatment of Alzheimer disease." | 7.78 | Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. ( Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW, 2012) |
| "The potential prothrombotic effect of the cyclooxygenase-2 (COX-2) inhibitor Rofecoxib (Vioxx) was investigated using murine thrombosis models." | 7.74 | Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. ( Gallacher, DJ; Hoylaerts, MF; Lijnen, HR; Lu, HR; Nagai, N, 2008) |
| "We conclude that under our experimental conditions, rofecoxib diminished platelet aggregation induced by different agonists and inhibited platelet-mediated thrombogenesis in an in vitro model of thrombosis." | 7.72 | Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. ( Arderiu, G; Escolar, G; Hernandez, MR; Pino, M; Serradell, M; Tonda, R, 2004) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 7.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "Main parameter was thrombus weight." | 5.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
| "Using an intention-to-treat analysis of adjudicated CVT deaths, we analyzed detailed patient-level data collected during 3 randomized placebo-controlled trials of rofecoxib versus placebo that had been designed to define the drug's possible role in the prevention or treatment of Alzheimer disease." | 3.78 | Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. ( Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW, 2012) |
| "It was predicted from the mechanism of action that, compared to older non-steroidal anti-inflammatory drugs, rofecoxib (Vioxx) would reduce gastrointestinal bleeding, but also that it would increase the occurrence of cardiovascular thrombosis." | 3.76 | Unbalanced reporting of benefits and harms in abstracts on rofecoxib. ( Gøtzsche, PC; Jørgensen, AW; Jørgensen, KJ, 2010) |
| "The potential prothrombotic effect of the cyclooxygenase-2 (COX-2) inhibitor Rofecoxib (Vioxx) was investigated using murine thrombosis models." | 3.74 | Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. ( Gallacher, DJ; Hoylaerts, MF; Lijnen, HR; Lu, HR; Nagai, N, 2008) |
| "We conclude that under our experimental conditions, rofecoxib diminished platelet aggregation induced by different agonists and inhibited platelet-mediated thrombogenesis in an in vitro model of thrombosis." | 3.72 | Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. ( Arderiu, G; Escolar, G; Hernandez, MR; Pino, M; Serradell, M; Tonda, R, 2004) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 3.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| " In the VIGOR gastrointestinal outcomes trial of >8000 patients, naproxen (an NSAID with aspirin-like sustained antiplatelet effects throughout its dosing interval) was associated with a significantly lower risk of CV events than was rofecoxib." | 2.42 | Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. ( Gertz, BJ; Reicin, A; Sperling, RS; Weir, MR, 2003) |
| " Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone)." | 2.41 | Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. ( Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR, 2001) |
| "Rofecoxib was withdrawn from the market on 30 September 2004 following the results of a randomized controlled trial." | 1.35 | Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? ( Bagheri, H; Grolleau, S; Lapeyre-Mestre, M; Montastruc, JL; Sommet, A, 2008) |
| "Main parameter was thrombus weight." | 1.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (87.10) | 29.6817 |
| 2010's | 4 (12.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sommet, A | 1 |
| Grolleau, S | 1 |
| Bagheri, H | 1 |
| Lapeyre-Mestre, M | 1 |
| Montastruc, JL | 1 |
| Nagai, N | 1 |
| Hoylaerts, MF | 1 |
| Gallacher, DJ | 1 |
| Lu, HR | 1 |
| Lijnen, HR | 1 |
| Baigent, C | 1 |
| Patrono, C | 1 |
| Jørgensen, AW | 1 |
| Jørgensen, KJ | 1 |
| Gøtzsche, PC | 1 |
| Kaber, G | 1 |
| Kaiser, B | 1 |
| Baumgärtel-Allekotte, D | 1 |
| Rauch, B | 1 |
| Nossmann, S | 1 |
| Heim, Kh | 1 |
| Weber, A | 1 |
| Nagy, N | 1 |
| Fischer, J | 1 |
| Schrör, K | 2 |
| Khan, M | 1 |
| Fraser, A | 1 |
| Madigan, D | 1 |
| Sigelman, DW | 1 |
| Mayer, JW | 1 |
| Furberg, CD | 1 |
| Avorn, J | 1 |
| Jaeschke, R | 1 |
| Gajewski, P | 1 |
| Brozek, J | 1 |
| Bannwarth, B | 1 |
| Ravaud, P | 1 |
| Dougados, M | 1 |
| Girardin, F | 1 |
| Siegenthaler, M | 1 |
| De Moerloose, P | 1 |
| Desmeules, J | 1 |
| Konstam, MA | 3 |
| Weir, MR | 2 |
| Sperling, RS | 3 |
| Reicin, A | 2 |
| Gertz, BJ | 2 |
| Hernandez, MR | 1 |
| Tonda, R | 1 |
| Pino, M | 1 |
| Serradell, M | 1 |
| Arderiu, G | 1 |
| Escolar, G | 1 |
| Umar, A | 1 |
| Boisseau, M | 1 |
| Yusup, A | 1 |
| Upur, H | 1 |
| Bégaud, B | 1 |
| Moore, N | 1 |
| Couzin, J | 1 |
| Bresalier, RS | 1 |
| Sandler, RS | 1 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Oxenius, B | 1 |
| Horgan, K | 1 |
| Lines, C | 1 |
| Riddell, R | 1 |
| Morton, D | 1 |
| Lanas, A | 1 |
| Baron, JA | 1 |
| Alpert, JS | 1 |
| Fries, S | 1 |
| Grosser, T | 1 |
| Price, TS | 1 |
| Lawson, JA | 1 |
| Kapoor, S | 1 |
| DeMarco, S | 1 |
| Pletcher, MT | 1 |
| Wiltshire, T | 1 |
| FitzGerald, GA | 2 |
| Rashid, A | 1 |
| Dale, G | 1 |
| Hennebry, T | 1 |
| Lagakos, SW | 1 |
| Steffel, J | 1 |
| Akhmedov, A | 1 |
| Fähndrich, C | 1 |
| Ruschitzka, F | 1 |
| Lüscher, TF | 1 |
| Tanner, FC | 1 |
| Mukherjee, D | 2 |
| Sibilia, J | 1 |
| Deray, G | 2 |
| Montalescot, G | 1 |
| Valat, JP | 1 |
| Héloire, F | 1 |
| Weber, AA | 1 |
| Heim, HK | 1 |
| Schumacher, M | 1 |
| Hohlfeld, T | 1 |
| Martínez-González, J | 1 |
| Badimon, L | 1 |
| Austin, S | 1 |
| Egan, K | 1 |
| Cheng, Y | 1 |
| Pratico, D | 1 |
| Shapiro, D | 2 |
| Barr, E | 2 |
| Reicin, AS | 1 |
| Yu, Q | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of [NCT00282386] | Phase 3 | 2,586 participants (Actual) | Interventional | 1999-12-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for rofecoxib and Thrombosis
| Article | Year |
|---|---|
Cox-2 inhibitors and the risk of cardiovascular thrombotic events.
Topics: Cyclooxygenase 2 Inhibitors; Humans; Lactones; Sulfones; Thrombosis | 2012 |
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Blood | 2003 |
Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 | 2006 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celeco | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.
Topics: Atherosclerosis; Cardiovascular Diseases; Consumer Product Safety; Cyclooxygenase 2; Cyclooxygenase | 2007 |
Cyclo-oxygenase products and atherothrombosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Epoprostenol; Humans; L | 2000 |
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu | 2001 |
Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.
Topics: Animals; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloox | 2002 |
4 trials available for rofecoxib and Thrombosis
| Article | Year |
|---|---|
Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib.
Topics: Aged; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Isoe | 2003 |
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin | 2005 |
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2006 |
Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers.
Topics: Adenosine Diphosphate; Adult; Aspirin; Atherosclerosis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxy | 2007 |
18 other studies available for rofecoxib and Thrombosis
| Article | Year |
|---|---|
Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?
Topics: Adverse Drug Reaction Reporting Systems; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; | 2008 |
Prothrombotic effect of Rofecoxib in a murine venous thrombosis model.
Topics: Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Femoral Artery; Jugular Veins; Lactone | 2008 |
Selective COX-2 inhibitors: where do we go from here?
Topics: Cyclooxygenase 2 Inhibitors; Humans; Lactones; Randomized Controlled Trials as Topic; Sulfones; Thro | 2008 |
Unbalanced reporting of benefits and harms in abstracts on rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Double-Blind Method; Gastrointest | 2010 |
Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit.
Topics: Animal Feed; Animals; Aorta; Aspirin; Atherosclerosis; Cholesterol; Cyclooxygenase 2; Cyclooxygenase | 2011 |
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.
Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Cardiovascular Diseases; Cyclooxygenase | 2012 |
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aspirin; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Hu | 2002 |
Rofecoxib interaction with oral anticoagulant acenocoumarol.
Topics: Acenocoumarol; Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Biological Av | 2003 |
Matters of the heart: assessing the cardiovascular safety of new drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy | 2003 |
Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Blood Pla | 2004 |
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxy | 2004 |
Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
Topics: Blood Pressure; Clinical Trials as Topic; Colonic Polyps; Cyclooxygenase Inhibitors; Drug and Narcot | 2004 |
The Vioxx debacle.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Approval; Humans; Lactones; | 2005 |
Cold leg in patient with high coated platelets: possible association with the use of rofecoxib.
Topics: Acute Disease; Blood Platelets; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Eptifibatide; | 2006 |
Time-to-event analyses for long-term treatments--the APPROVe trial.
Topics: Adenomatous Polyps; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Follow-Up Studies | 2006 |
Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Celecoxib; Cell Line; Endothelium, Vascula | 2006 |
Cardiovascular safety of COX-2 inhibitors.
Topics: Cardiovascular Physiological Phenomena; Celecoxib; Consumer Product Safety; Cyclooxygenase Inhibitor | 2001 |
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T | 2002 |